AKASA
AKASA builds generative AI software for hospital revenue cycle management, combining healthcare-specific LLMs trained on 43 million-plus clinical documents with in-house RCM expertise. It serves large U.S. health systems and academic medical centers via at-risk, performance-based multi-year contracts.
- Company typePrivate
- Founded2019
- HeadquartersSan Francisco, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What AKASA does
AKASA is a private, venture-backed healthcare technology company founded in 2018 and headquartered in South San Francisco that builds generative AI software for hospital revenue cycle management (RCM). Its proprietary AKASA Platform combines healthcare-specific large language models — fine-tuned on 43 million-plus clinical documents and on each customer's own clinical and financial data — with an in-house bench of RCM experts averaging more than 15 years of industry experience. Product surface includes Coding Optimizer and CDI Optimizer (unified as the Prebill Optimization Suite, which reviews 100% of inpatient encounters before billing), AI Advisor (a clinical research assistant for prior authorization, denials, and peer-to-peer preparation), Auth Status, and Claim Status. The platform integrates with Epic and Cerner via standards-based API/EDI and is HIPAA-compliant, SOC 2 Type 2 certified, HITRUST CSF/R2 certified, and aligned with NIST 800-53 and CIS controls on AWS infrastructure.
AKASA serves large U.S. health systems and academic medical centers — Cleveland Clinic, Stanford Health Care, Johns Hopkins Health System, Duke University Health System, Methodist Health System, Nebraska Methodist Health System, and Montage Health, among others — totaling more than 650 hospitals and 6,500 outpatient facilities across all 50 states. The company goes to market through a high-touch enterprise sales motion (30–45 minute RCM-expert-led demos, dedicated Epic/Cerner integration teams, multi-year contracts) and is monetized on an at-risk, performance-based pricing model with no upfront fees: AKASA only invoices after measurable financial improvement is realized, aligning vendor incentives with customer yield, denial reduction, and accuracy outcomes. Reported customer outcomes include a $30M gross yield increase and 86% efficiency improvement at Methodist Health System, a 40% improvement in POA capture at Cleveland Clinic, a 13% decrease in A/R days and 80,000+ claims automated at Montage Health, and a 22% reduction in auth work queue volume. The company has raised approximately $205M in disclosed equity funding across rounds led by Andreessen Horowitz, BOND, Costanoa Ventures, and Coatue.
The company's strategic posture is mid-cycle-led: it is consolidating coding, CDI, prior authorization, and claim status automation onto a single AI-native workflow, deepening EHR integration, and converting flagship academic medical centers into enterprise-wide deployments — most visibly through the Cleveland Clinic partnership, which expanded from coding to enterprise-wide CDI in roughly six months in 2025. AKASA is geographically domestic (United States only) and operates as a remote-friendly organization with hubs in the Bay Area, New York, and Denver, and team members across 29 states.
AKASA firmographics
Firmographics- Name
- AKASA
- Legal name
- AKASA, Inc.
- Website
- https://akasa.com/
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- AKASA builds generative AI software for hospital revenue cycle management, combining healthcare-specific LLMs trained on 43 million-plus clinical documents with in-house RCM expertise. It serves large U.S. health systems and academic medical centers via at-risk, performance-based multi-year contracts.
- Ownership category
- akta.pro rank
AKASA industry classification
Industry- Product category
- Healthcare Revenue Cycle Management Software
- NAICS
- Computer Systems Design and Related Services (5415), Other Computer Related Services (541519)
- SIC
- Services-Prepackaged Software (7372), Services-Health Services (8000), Services-Computer Integrated Systems Design (7373)
- akta.pro primary industry
- EHR Extensions, APIs, App Marketplaces & SMART-on-FHIR Apps (HLACAAAN)
- akta.pro secondary industries
- Payer-Provider Data Exchange (X12, prior auth, claims/clinical attachment) (HLACABAK), EHR Implementation, Optimization, Training & Managed Services (HLACAAAL)
Keywords
Where AKASA is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
AKASA business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Performance-based fees from healthcare AI/automation deployments: AKASA operates on an at-risk, outcome-based pricing model: 'No upfront fees — AKASA only invoices after measurable financial improvement is realized.' Customers pay based on achieved yield, denials reduction, or other measurable RCM KPIs tied to the deployment.
- Demo / Sales-led enterprise contracts: Revenue is sourced through a 30-45 minute enterprise sales conversation led by an RCM expert; deal structure is contract-based with quoted pricing per health system, not publicly listed.
- Mid-cycle RCM automation (Coding Optimizer + CDI Optimizer): Primary mid-cycle product offering bundled into the Prebill Optimization Suite; custom-trained GenAI deployed per health system to drive yield, accuracy, and quality outcomes with at-risk pricing.
- Patient Access automation (Auth Status) and Business Office automation (Claim Status): Ancillary revenue streams from AI/ML-driven prior authorization status checking and claim status automation; priced and bundled as part of broader AKASA authorizations management and claim management product lines.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Outcome Based/ Performance | Multi-year contract | Performance-based / outcome-based enterprise pricing |
| Other | Multi-year contract | At-risk, results-driven contract pricing |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels8 records
AKASA product offering
Product offeringCore offering
AKASA builds a generative AI platform purpose-built for the healthcare revenue cycle, combining healthcare-specific large language models fine-tuned on each health system's own clinical and financial data with an in-house team of RCM experts. The platform powers six solutions — Prebill Optimization Suite (unified coding + CDI), Coding Optimizer, CDI Optimizer, AI Advisor, Auth Status, and Claim Status — that review 100% of inpatient encounters prebill, surface missed codes and documentation gaps, automate prior authorization and claim status workflows, and integrate with Epic and Cerner EHRs.
Product overview
AKASA offers a unified platform-plus-modules architecture for generative AI in the healthcare revenue cycle. The AKASA Platform is the foundational layer that combines proprietary, healthcare-trained generative AI/LLMs with deep revenue cycle expertise and integrates with EHRs such as Epic and Cerner. Built on this platform are six named offerings: the Prebill Optimization Suite (which itself unifies the Coding Optimizer and CDI Optimizer into a single prebill workflow reviewing 100% of inpatient encounters), the standalone AKASA Coding Optimizer and AKASA CDI Optimizer modules, the AKASA AI Advisor research assistant for revenue cycle teams, and two process automation solutions — AKASA Auth Status and AKASA Claim Status — that automate prior authorization and claim status workflows. Together, the platform and these modules address the mid-revenue cycle (coding, CDI) as well as adjacent patient access and business office workflows for hospitals, health systems, and academic medical centers.
Differentiator
Problem solved
Functional benefit
Brands
- AKASA Coding Optimizer™: Generative AI-powered coding solution that reviews coded inpatient encounters and relevant documentation across all service lines to identify missed revenue, quality metrics, and denial/compliance risks.
- AKASA CDI Optimizer™
- AKASA Prebill Optimization Suite
- AKASA AI Advisor
- AKASA Auth Status
- AKASA Claim Status
Products and services
- AKASA Platform Generative AI-powered platform that combines proprietary GenAI/LLMs with deep RCM expertise, trained on 43+ million clinical documents and on each health system's own clinical and financial data, with components for Generative AI, Experts, Integration, Reporting, and Security. Powers all AKASA solutions and supports standards-based integrations with Epic and Cerner EHRs. Sold to enterprise health systems and academic medical centers.
- Prebill Optimization Suite Unified mid-revenue cycle platform that reviews 100% of inpatient encounters prebill using custom-trained GenAI, combining Coding Optimizer and CDI Optimizer into a single integrated workflow that surfaces documentation gaps, missed codes, and quality/compliance opportunities before claims are released. Sold to enterprise hospitals and health systems.
- AKASA Coding Optimizer GenAI-powered coding solution that re-codes every inpatient encounter across all service lines from scratch, identifying missed codes, unsupported codes, sequencing improvements, missed CC/MCCs, denial risks, and quality indicators, with evidence-backed suggestions and confidence scores for coder validation. Sold to enterprise hospitals, health systems, and academic medical centers.
- AKASA CDI Optimizer Generative AI assistant for Clinical Documentation Integrity that analyzes vitals, labs, flow sheets, medications, clinical notes, and other complex multi-modal data to surface documentation gaps and evidence-based clinical queries for CDI specialists, enabling real-time collaboration with coding teams. Sold to enterprise hospitals, health systems, and academic medical centers.
- AKASA AI Advisor Generative AI research assistant for revenue cycle teams that connects to live EHR patient data, helping non-clinical staff surface clinical documentation, summarize records, draft prior authorization letters, and write denial appeal letters with cited answers across prior auth, denials, peer-to-peer prep, and clinical validation use cases. Sold to enterprise hospitals and health systems.
- AKASA Auth Status AI-powered automation, combining machine learning with expert-in-the-loop oversight, that checks the status of prior authorization requests on payer portals, interprets results, and logs status back into the EHR to reduce manual auth follow-ups for patient access teams. Sold to enterprise hospitals and health systems.
- AKASA Claim Status AI-powered claim status automation that proactively checks claim status with payers across portal search options, interprets results, and routes accounts needing intervention to staff work queues, reducing A/R days and removing accounts from staff queues. Sold to enterprise hospitals and health systems.
Quantifiable outcome
- 40% improvement in POA capture at Cleveland Clinic
- +5 more outcomes
Companies that use AKASA
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles1 record
AKASA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability11 records
Feature8 records
AKASA partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered flagship, core and minor.
- Cleveland ClinicflagshipDeep, multi-stage strategic partnership. Cleveland Clinic completed the rollout of AKASA's AI coding tool in all U.S. locations over four months, processing tens of thousands of encounters. On Oct 13, 2025, AKASA announced Cleveland Clinic was the first organization to pilot the CDI Optimizer, with deployment planned across all U.S. locations. Co-presenters at HFMA 2025, AHIMA 2025, and ACDIS 2026 Virtual Summit. Cleveland Clinic is processing 100% of its enterprise inpatient volume through AKASA, recognized by HIT Consultant as 'one of the most comprehensive real-world uses of GenAI in healthcare finance.'
- Johns Hopkins Health SystemcoreCo-developed whitepaper on deploying generative AI and LLMs to improve prior authorization. Joint case study demonstrated reductions in operating costs, enhanced productivity, and revenue improvements — used as a customer reference and thought leadership asset.
- Stanford Health CarecoreStanford Health Care has been an AKASA customer since 2021 and co-presented at HFMA Western Region Symposium 2025. Uses AKASA's GenAI solutions in patient access to automate repetitive authorization follow-ups while maintaining 90% financial clearance rate. Stanford leaders have publicly endorsed AKASA's tools for productivity and denial reduction.
- Montage HealthcoreMulti-year collaboration expanding from claim status automation to auth status and additional patient access workflows. Flagship case study published on akasa.com/case-studies/montage-auth-status documenting 13% decrease in A/R days, 300+ hours/month staff time saved, 22% reduction in auth work queue volume, and 80,000+ claims automated in ~1 year.
- Methodist Health SystemcoreFlagship customer and case study subject. 4 hospitals, 33 clinics, $950M net patient revenue. Deployed AKASA Claim Status with documented results: $30M gross yield increase, 86% efficiency improvement, 71.3% of accounts removed from staff queues, 13.8 FTE production equivalent. Featured in case study, webinar, and resource materials.
- Duke University Health SystemcoreImplementing AKASA's generative AI solutions to address complex medical coding challenges where a typical patient record spans 50,000 words across 59 documents. Reports improved accuracy and efficiency and plans to expand AI to denial management. Co-presented with Cleveland Clinic and AKASA at AHIMA 2025 panel.
- Nebraska Methodist Health SystemcoreFeatured AKASA customer producing video case study content on generative AI and coding. Gained $2 million from AI-assisted coding per Healthcare IT News. Director of HIM, Clinical Coding, CDI, and Utilization Management endorsed AKASA Coding Optimizer publicly.
- EpiccoreStandards-based integration with Epic EHR systems via API/EDI; supported by a dedicated integration team. AKASA is Epic/Cerner-ready, and the Cleveland Clinic, Montage Health, and Methodist Health System deployments all rely on Epic integration.
- CernercoreStandards-based integration with Cerner EHR systems via API/EDI; supported by a dedicated integration team.
- Amazon Web Services (AWS)coreCore cloud infrastructure provider; AKASA utilizes AWS infrastructure with CIS Level 1 hardening, ZeroTrust VPN, FIPS 140-2 encryption, and 'Everything as code' infrastructure operations.
- AHIMA (American Health Information Management Association)minorCo-presented conference sessions at AHIMA 2024 and AHIMA 2025; AKASA's Director of Coding Mindy Harris led AHIMA24 conference presentation on 'Why Medical Coding Needs Generative AI.' Cleveland Clinic, Duke University Health System, and AKASA shared experiences at AHIMA 2025 panel.
- HFMA (Healthcare Financial Management Association)coreCo-published 'The Revenue Cycle Intelligence Report' (HFMA + AKASA survey of 500+ healthcare finance leaders); co-hosted panel at HFMA Annual Conference in Denver with Cleveland Clinic leadership; partnered on encore webinar. AKASA leverages HFMA Pulse Survey program for survey research.
Scale indicators12 records
Recent moves6 records
Expansion highlights5 records
AKASA competitors and assessment
Company assessmentDirect peers
- Waystar: Public revenue cycle management platform serving US hospitals and health systems across claims management, patient access, and analytics. Directly comparable to AKASA as a horizontal RCM tech stack with overlapping buyer (CFO/Revenue Cycle leaders) and use cases (claim status, prior auth, denials), though AKASA differentiates on GenAI vs. rules-based workflows.
- R1 RCM: End-to-end revenue cycle management solutions provider for hospitals and health systems, now owned by TowerBrook and CD&R after a take-private. Comparable to AKASA in serving large health systems with RCM technology and services, and a primary incumbent competitor in mid-cycle and patient access automation.
- Olive AI: AI-for-healthcare-automation company (now restructuring under Healthcare.GG) that targeted revenue cycle, supply chain, and prior authorization workflows for hospitals. Historically the most direct AI-RCM competitor to AKASA, with overlapping product surface in coding, claim status, and prior auth automation.
Emerging players
- Cohere Health: AI-powered prior authorization platform partnering with health plans and providers to streamline authorization decisions. Comparable to AKASA's Auth Status and AI Advisor use cases on the payer-provider prior authorization workflow, though Cohere is more payer-side oriented.
- Anterior: AI-native company applying large language models to prior authorization and clinical documentation for health plans and providers. Closest emerging direct competitor to AKASA's AI Advisor / Auth Status products with a similar GenAI-first approach to clinical and authorization workflows.
- Infinx: Healthcare revenue cycle company combining AI-driven prior authorization, eligibility, and patient access automation with services. Comparable to AKASA's Auth Status, AI Advisor, and patient access offerings for hospitals and imaging centers.
- Cedar: Patient engagement and billing platform for health systems using AI to personalize patient financial experiences and reduce friction in payments. Adjacent to AKASA on the patient-facing end of the revenue cycle, though focused on patient pay rather than mid-cycle coding/CDI.
Broad incumbents
- Optum (UnitedHealth Group): Broad incumbent in healthcare technology, RCM services, and analytics as part of UnitedHealth Group. Overlaps with AKASA across revenue cycle, prior authorization, and AI-driven documentation, but at much greater scale and as one offering among many in a vertically integrated portfolio.
- Health Catalyst: Data and analytics platform for health systems with adjacent RCM and clinical documentation improvement modules. Comparable to AKASA in selling to enterprise health systems and academic medical centers, though its core strength is analytics rather than GenAI-driven coding/CDI automation.
- Experian Health: Healthcare division of Experian providing identity, eligibility, claims management, and patient access solutions to hospitals and payers. Comparable to AKASA on claim status automation, eligibility verification, and patient access workflows for large health systems.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
AKASA social profiles
Digital presenceAKASA compliance and trust
Trust signalCompliance6 records
AKASA financial estimates
Financial estimateRevenue estimate
Valuation estimate
AKASA leadership team
Management profileNumber of profiles
Profiles14 records
AKASA funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AKASA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AKASA
What does AKASA do?
AKASA builds a generative AI platform purpose-built for the healthcare revenue cycle, combining healthcare-specific large language models fine-tuned on each health system's own clinical and financial data with an in-house team of RCM experts. The platform powers six solutions — Prebill Optimization Suite (unified coding + CDI), Coding Optimizer, CDI Optimizer, AI Advisor, Auth Status, and Claim Status — that review 100% of inpatient encounters prebill, surface missed codes and documentation gaps, automate prior authorization and claim status workflows, and integrate with Epic and Cerner EHRs.
Is AKASA a public or private company?
AKASA is a private company. It is classified as venture growth investor backed and is currently operating.
When was AKASA founded?
AKASA was founded in 2019. It employs 101 to 250 people.
Where is AKASA based?
AKASA is headquartered in San Francisco, United States, in the North America region.
How does AKASA make money?
Four revenue lines are on record. Performance-based fees from healthcare AI/automation deployments are the primary driver. The others are demo / Sales-led enterprise contracts, mid-cycle RCM automation (Coding Optimizer + CDI Optimizer) and patient Access automation (Auth Status) and Business Office automation (Claim Status).
Who are AKASA's main competitors?
Direct peers on record are Waystar, R1 RCM and Olive AI. Emerging players are Cohere Health, Anterior, Infinx and Cedar. Broad incumbents are Optum (UnitedHealth Group), Health Catalyst and Experian Health.
Does AKASA have an API?
No public API is recorded for AKASA.
What industry is AKASA in?
AKASA's product category is Healthcare Revenue Cycle Management Software. Its primary akta.pro industry code is HLACAAAN, EHR Extensions, APIs, App Marketplaces & SMART-on-FHIR Apps, with a secondary code of HLACABAK, Payer-Provider Data Exchange (X12, prior auth, claims/clinical attachment). Its NAICS code is 5415 and its SIC code is 7372.